ATE361318T1 - Polypeptiden, die die april-vermittelte aktivierung von t-und b-zellen hemmen - Google Patents
Polypeptiden, die die april-vermittelte aktivierung von t-und b-zellen hemmenInfo
- Publication number
- ATE361318T1 ATE361318T1 AT01935466T AT01935466T ATE361318T1 AT E361318 T1 ATE361318 T1 AT E361318T1 AT 01935466 T AT01935466 T AT 01935466T AT 01935466 T AT01935466 T AT 01935466T AT E361318 T1 ATE361318 T1 AT E361318T1
- Authority
- AT
- Austria
- Prior art keywords
- april
- taci
- bcma
- cell
- agp
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20403900P | 2000-05-12 | 2000-05-12 | |
US21459100P | 2000-06-27 | 2000-06-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE361318T1 true ATE361318T1 (de) | 2007-05-15 |
Family
ID=26899121
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01935466T ATE361318T1 (de) | 2000-05-12 | 2001-05-14 | Polypeptiden, die die april-vermittelte aktivierung von t-und b-zellen hemmen |
Country Status (10)
Country | Link |
---|---|
US (2) | US6774106B2 (de) |
EP (1) | EP1280826B1 (de) |
JP (1) | JP2003533218A (de) |
AT (1) | ATE361318T1 (de) |
AU (3) | AU2001263114A1 (de) |
CA (1) | CA2408617A1 (de) |
DE (1) | DE60128216T2 (de) |
ES (1) | ES2287130T3 (de) |
MX (1) | MXPA02011130A (de) |
WO (2) | WO2001087979A2 (de) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7217788B2 (en) | 1996-03-14 | 2007-05-15 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta polypeptides |
US6541224B2 (en) | 1996-03-14 | 2003-04-01 | Human Genome Sciences, Inc. | Tumor necrosis factor delta polypeptides |
US6812327B1 (en) | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
US8212004B2 (en) * | 1999-03-02 | 2012-07-03 | Human Genome Sciences, Inc. | Neutrokine-alpha fusion proteins |
US7833529B1 (en) | 1999-01-07 | 2010-11-16 | Zymogenetics, Inc. | Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor |
EP1210425B2 (de) * | 1999-08-17 | 2015-06-17 | Biogen MA Inc. | Baff rezeptor (bcma), ein immunoregulatorisches mittel |
UA74798C2 (uk) * | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
ATE329610T1 (de) * | 2000-02-16 | 2006-07-15 | Genentech Inc | Anti-april antikörper und hybridomazellen |
US20040013674A1 (en) * | 2001-04-27 | 2004-01-22 | Christine Ambrose | Taci as an anti-tumor agent |
US7371388B1 (en) | 2000-05-04 | 2008-05-13 | Human Genome Sciences, Inc. | Treatment of Sjogren's syndrome by administration of TR18 polypeptides |
PT2281843T (pt) * | 2000-06-16 | 2017-01-02 | Human Genome Sciences Inc | Anticorpos que se ligam imunoespecificamente a blys |
US7220840B2 (en) | 2000-06-16 | 2007-05-22 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator protein |
US7879328B2 (en) * | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
EP2267018A3 (de) * | 2000-08-18 | 2011-04-20 | Human Genome Sciences, Inc. | Polypeptide zur Bindung an das B-Lymphozyten-stimulatorische Protein (BLyS) |
US20030091565A1 (en) * | 2000-08-18 | 2003-05-15 | Beltzer James P. | Binding polypeptides and methods based thereon |
WO2002046231A2 (en) * | 2000-12-07 | 2002-06-13 | The University Of British Columbia | Caml-binding peptides |
EP2301971A1 (de) * | 2001-02-20 | 2011-03-30 | ZymoGenetics, L.L.C. | Antikörper, die sowohl BCMA als auch TACI binden |
DK1436003T3 (da) * | 2001-05-24 | 2010-03-15 | Zymogenetics Inc | TACI-immunoglobulin-fusionsproteiner |
EP1401870A4 (de) | 2001-05-24 | 2006-04-19 | Human Genome Sciences | Antikörper gegen tumor necrosis factor delta (april) |
HUP0500992A3 (en) * | 2001-08-03 | 2007-11-28 | Genentech Inc | Tacis and br3 polypeptides and uses thereof |
AU2002364954A1 (en) * | 2001-11-16 | 2003-07-15 | Human Genome Sciences, Inc. | ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS |
JP2005533863A (ja) * | 2002-07-25 | 2005-11-10 | ジェネンテック・インコーポレーテッド | Taci抗体とその用途 |
AU2003284260B2 (en) * | 2002-10-11 | 2010-06-03 | Zymogenetics, Inc. | Production of homotrimeric fusion proteins |
WO2004060911A2 (en) | 2002-12-30 | 2004-07-22 | Amgen Inc. | Combination therapy with co-stimulatory factors |
US20050163775A1 (en) * | 2003-06-05 | 2005-07-28 | Genentech, Inc. | Combination therapy for B cell disorders |
PT2272868E (pt) | 2003-06-05 | 2015-07-07 | Genentech Inc | Terapêutica de combinação para distúrbios de células b |
US20050118728A1 (en) * | 2003-07-02 | 2005-06-02 | Caldwell Kevin K. | Two-layer antibody capture system |
JP2008505607A (ja) * | 2004-01-29 | 2008-02-28 | ジェネンテック・インコーポレーテッド | Bcmaの細胞外ドメインの変異体とその使用法 |
EP1812472A1 (de) * | 2004-11-04 | 2007-08-01 | Genentech, Inc. | An baff und/oder april bindende polypeptide |
US7947805B2 (en) | 2004-12-23 | 2011-05-24 | Merck Serono S.A. | BCMA polypeptides and uses thereof |
AR059945A1 (es) * | 2005-08-09 | 2008-05-14 | Zymogenetics Inc | Metodos para tratar afecciones malignas de celulas b que utilizan una molecula de fusion taci-ig |
CA2618763A1 (en) | 2005-08-09 | 2007-02-15 | Zymogenetics, Inc. | Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules |
AU2006344395B2 (en) * | 2005-10-13 | 2013-05-02 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive diseases |
US9168286B2 (en) * | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
CA2629306A1 (en) * | 2005-11-23 | 2007-05-31 | Genentech, Inc. | Methods and compositions related to b cell assays |
US8211649B2 (en) | 2006-03-31 | 2012-07-03 | Human Genome Sciences, Inc. | Methods of diagnosing and prognosing hodgkin's lymphoma |
NZ572373A (en) | 2006-05-15 | 2012-02-24 | Ares Trading Sa | Methods for treating rheumatoid arthritis using a taci-ig fusion molecule |
EA017733B1 (ru) * | 2006-08-28 | 2013-02-28 | Арес Трейдинг С.А. | СПОСОБ ОЧИСТКИ Fc-СЛИТЫХ БЕЛКОВ |
LT2061803T (lt) * | 2006-08-28 | 2019-11-25 | Ares Trading Sa | Fc turinčių baltymų gryninimo būdas |
WO2008088422A2 (en) * | 2006-10-25 | 2008-07-24 | Amgen Inc. | Toxin peptide therapeutic agents |
WO2009052293A1 (en) | 2007-10-16 | 2009-04-23 | Zymogenetics, Inc. | Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease |
PL2219675T3 (pl) * | 2007-11-12 | 2014-04-30 | Ares Trading Sa | Formulacja dla białek fuzyjnych TACI-immunoglobulina |
JP5739326B2 (ja) | 2008-04-25 | 2015-06-24 | ザイモジェネティクス, インコーポレイテッド | B細胞上でのbcmaタンパク発現レベル及び診断法における使用 |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
US20110014190A1 (en) * | 2009-02-12 | 2011-01-20 | Human Genome Sciences, Inc. | Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance |
SI2403528T1 (sl) * | 2009-03-02 | 2016-07-29 | Aduro Biotech Holdings, Europe B.V. | Protitelesa proti proliferacijo inducirajočemu ligandu (april) |
US8728730B2 (en) | 2009-09-03 | 2014-05-20 | Genentech, Inc. | Methods for treating, diagnosing, and monitoring rheumatoid arthritis |
WO2011109280A1 (en) | 2010-03-05 | 2011-09-09 | Lerner Research Institute | Methods and compositions to treat immune-mediated disorders |
ES2712102T3 (es) * | 2010-09-10 | 2019-05-09 | Tigenix S A U | Medios y métodos de cultivo de células madre |
MX353143B (es) | 2011-02-28 | 2017-12-20 | Genentech Inc | Marcadores biologicos y metodos para pronosticar respuesta a antagonistas de celulas b. |
TWI679212B (zh) * | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對bcma之e3以及cd3的結合分子 |
AR095374A1 (es) | 2013-03-15 | 2015-10-14 | Amgen Res (Munich) Gmbh | Moléculas de unión para bcma y cd3 |
NL2011406C2 (en) * | 2013-09-06 | 2015-03-10 | Bionovion Holding B V | Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides. |
US10435453B2 (en) | 2014-02-07 | 2019-10-08 | Mcmaster University | Trifunctional T cell-antigen coupler and methods and uses thereof |
WO2016003876A1 (en) | 2014-07-03 | 2016-01-07 | Oklahoma Medical Research Foundation | Treatment of multiple sclerosis and neuromyelitis optica |
SI3380522T1 (sl) | 2015-11-25 | 2024-02-29 | Visterra, Inc. | Molekule protitelesa proti APRIL in uporabe le-teh |
JP7432363B2 (ja) | 2016-06-21 | 2024-02-16 | テネオバイオ, インコーポレイテッド | Cd3結合抗体 |
FI4050034T3 (fi) | 2016-09-14 | 2024-06-10 | Teneoone Inc | Cd3:een sitoutuvia vasta-aineita |
EP4215548A1 (de) | 2016-12-21 | 2023-07-26 | Teneobio, Inc. | Nur schwerkettige anti-bcma-antikörper |
AU2018289493A1 (en) * | 2017-06-20 | 2019-12-12 | Dana-Farber Cancer Institute, Inc. | Methods for modulating regulatory T cells, regulatory B cells, and immune responses using modulators of the APRIL-TACI interaction |
EP3642237A2 (de) | 2017-06-20 | 2020-04-29 | Teneobio, Inc. | Nur schwerketten-anti-bcma-antikörper |
US11517591B2 (en) * | 2017-09-01 | 2022-12-06 | Dana-Farber Cancer Institute, Inc. | Immunogenic peptides specific to BCMA and TACI antigens |
EP3694997A4 (de) | 2017-10-12 | 2021-06-30 | Mcmaster University | T-zellen-antigen-koppler mit y182t-mutation und verfahren und verwendungen davon |
EP3694871A4 (de) | 2017-10-13 | 2021-11-10 | Harpoon Therapeutics, Inc. | B-zellreifungs-antigenbindende proteine |
CU20200089A7 (es) | 2018-06-01 | 2021-07-02 | Novartis Ag | Moléculas de unión contra bcma |
US11110123B2 (en) | 2018-07-17 | 2021-09-07 | Triumvira Immunologics Usa, Inc. | T cell-antigen coupler with various construct optimizations |
AU2019346466A1 (en) | 2018-09-25 | 2021-05-20 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
CA3140816A1 (en) | 2019-06-14 | 2020-12-17 | Nathan Trinklein | Multispecific heavy chain antibodies binding to cd22 and cd3 |
WO2021121250A1 (zh) * | 2019-12-17 | 2021-06-24 | 深圳市菲鹏生物治疗股份有限公司 | Bcma结合抗体及其用途 |
CA3176792C (en) | 2020-04-29 | 2024-06-18 | Katherine HARRIS | Anti-cd3 and anti-bcma bispecific antibodies wth modified heavy chain constant regions |
KR20230029622A (ko) | 2020-05-08 | 2023-03-03 | 알파인 이뮨 사이언시즈, 인코포레이티드 | April 및 baff 억제 면역조절 단백질 및 사용 방법 |
WO2022256449A1 (en) | 2021-06-01 | 2022-12-08 | Triumvira Immunologics Usa, Inc. | Claudin 18.2 t cell-antigen couplers and uses thereof |
US11453723B1 (en) | 2021-06-25 | 2022-09-27 | Mcmaster University | BCMA T cell-antigen couplers and uses thereof |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4289872A (en) * | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4699880A (en) | 1984-09-25 | 1987-10-13 | Immunomedics, Inc. | Method of producing monoclonal anti-idiotype antibody |
US5229490A (en) * | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
CA2118130A1 (en) | 1992-04-14 | 1993-10-28 | Jean M. J. Frechet | Dendritic based macromolecules and method of production |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
CA2665133A1 (en) | 1996-10-25 | 1998-05-07 | Human Genome Sciences, Inc. | Neutrokine .alpha. |
WO1998027114A2 (en) | 1996-12-17 | 1998-06-25 | Schering Corporation | Mammalian cell surface antigens; related reagents |
US5969102A (en) * | 1997-03-03 | 1999-10-19 | St. Jude Children's Research Hospital | Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof |
CA2232743A1 (en) | 1997-04-02 | 1998-10-02 | Smithkline Beecham Corporation | A tnf homologue, tl5 |
CA2292899A1 (en) | 1997-06-06 | 1998-12-10 | Regeneron Pharmaceuticals, Inc. | Ntn-2 member of tnf ligand family |
IL133315A0 (en) | 1997-06-06 | 2001-04-30 | Regeneron Pharma | Ntn-2 member of tnf ligand family |
US6171787B1 (en) | 1997-06-26 | 2001-01-09 | Abbott Laboratories | Member of the TNF family useful for treatment and diagnosis of disease |
WO1999011791A2 (en) | 1997-09-05 | 1999-03-11 | University Of Washington | Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents |
CA2303424A1 (en) | 1997-09-12 | 1999-03-18 | Jurg Tschopp | Kay - a novel immune system protein |
HUP0004611A3 (en) * | 1997-09-12 | 2002-04-29 | Apotech R & D Sa | April- a novel protein with growth effects |
US6297022B1 (en) | 1997-10-08 | 2001-10-02 | Smithkline Beecham Corporation | Method of identifying agonists and antagonists for tumor necrosis related receptor TR1 |
AU1700999A (en) | 1997-11-26 | 1999-06-15 | Eli Lilly And Company | Tnf ligand family gene |
NZ504548A (en) | 1997-12-03 | 2003-06-30 | Genentech Inc | Polypeptides and nucleic acids encoding human chordin |
WO1999033980A2 (en) | 1997-12-30 | 1999-07-08 | Chiron Corporation | Members of tnf and tnfr families |
AU2212299A (en) | 1998-01-05 | 1999-07-26 | Genentech Inc. | Compositions and methods for the treatment of tumor |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
EP1141274B2 (de) * | 1999-01-07 | 2014-11-12 | ZymoGenetics, Inc. | Lösliche rezeptoren br43x2 und verfahren zu deren therapeutischen verwendung |
WO2000068378A1 (en) * | 1999-05-06 | 2000-11-16 | National Jewish Medical And Research Center | Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof |
EP1210425B2 (de) * | 1999-08-17 | 2015-06-17 | Biogen MA Inc. | Baff rezeptor (bcma), ein immunoregulatorisches mittel |
UA74798C2 (uk) * | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
ATE329610T1 (de) * | 2000-02-16 | 2006-07-15 | Genentech Inc | Anti-april antikörper und hybridomazellen |
-
2001
- 2001-05-14 AT AT01935466T patent/ATE361318T1/de not_active IP Right Cessation
- 2001-05-14 ES ES01935466T patent/ES2287130T3/es not_active Expired - Lifetime
- 2001-05-14 MX MXPA02011130A patent/MXPA02011130A/es active IP Right Grant
- 2001-05-14 JP JP2001585195A patent/JP2003533218A/ja not_active Withdrawn
- 2001-05-14 US US09/854,864 patent/US6774106B2/en not_active Expired - Fee Related
- 2001-05-14 US US09/855,158 patent/US20020086018A1/en not_active Abandoned
- 2001-05-14 WO PCT/US2001/015567 patent/WO2001087979A2/en active Application Filing
- 2001-05-14 EP EP01935466A patent/EP1280826B1/de not_active Expired - Lifetime
- 2001-05-14 AU AU2001263114A patent/AU2001263114A1/en not_active Abandoned
- 2001-05-14 WO PCT/US2001/015504 patent/WO2001087977A2/en active IP Right Grant
- 2001-05-14 AU AU6155701A patent/AU6155701A/xx active Pending
- 2001-05-14 AU AU2001261557A patent/AU2001261557B2/en not_active Ceased
- 2001-05-14 DE DE60128216T patent/DE60128216T2/de not_active Expired - Fee Related
- 2001-05-14 CA CA002408617A patent/CA2408617A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2408617A1 (en) | 2001-11-22 |
US20020081296A1 (en) | 2002-06-27 |
US6774106B2 (en) | 2004-08-10 |
DE60128216D1 (de) | 2007-06-14 |
DE60128216T2 (de) | 2008-01-10 |
WO2001087977A2 (en) | 2001-11-22 |
MXPA02011130A (es) | 2003-03-10 |
ES2287130T3 (es) | 2007-12-16 |
AU2001263114A1 (en) | 2001-11-26 |
US20020086018A1 (en) | 2002-07-04 |
WO2001087979A3 (en) | 2002-05-30 |
WO2001087979A2 (en) | 2001-11-22 |
AU2001261557B2 (en) | 2005-06-30 |
AU6155701A (en) | 2001-11-26 |
JP2003533218A (ja) | 2003-11-11 |
EP1280826A2 (de) | 2003-02-05 |
WO2001087977A3 (en) | 2002-06-20 |
EP1280826B1 (de) | 2007-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE361318T1 (de) | Polypeptiden, die die april-vermittelte aktivierung von t-und b-zellen hemmen | |
HUS1700012I1 (hu) | Bruton-tirozinkináz inhibitorok | |
EA200501810A1 (ru) | Композиция конъюгированного лекарственного средства | |
ATE442850T1 (de) | Kappa-opioid-rezeptor-liganden | |
ATE399553T1 (de) | Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen | |
EA200601776A1 (ru) | Метадоновые композиции местного действия и способы их применения | |
GB2431346C (en) | A combination composition comprising paracetamol and ibuprofen | |
SG149872A1 (en) | Antagonists of the bradykinin b1 receptor | |
RS89104A (en) | Novel antagonists of mcp proteins | |
TNSN05315A1 (en) | Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular antagonist | |
ATE286074T1 (de) | Gegen ccr5 gerichtete antikörperkonstrukte und ihre verwendung in der behandlung von autoimmunkrankheiten | |
EP1611151A4 (de) | Stq-peptide | |
EA200600314A1 (ru) | Использование растворимого cd164 при воспалительных и/или аутоимунных нарушениях | |
ATE414776T1 (de) | Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |